AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM185.54+3.01 (+1.65%) ▲|QCOM174.78+6.04 (+3.58%) ▲|RTX199.49-1.30 (-0.65%) ▼|SBUX102.27-2.20 (-2.11%) ▼|SCHW108.52-0.78 (-0.71%) ▼|SO88.89+0.78 (+0.89%) ▲|SPG211.61+2.17 (+1.04%) ▲|T25.50-0.18 (-0.70%) ▼|TMO605.92-7.86 (-1.28%) ▼|TMUS179.68-1.84 (-1.01%) ▼|TSLA367.79+13.71 (+3.87%) ▲|TXN257.14-1.30 (-0.50%) ▼|UBER73.24-2.52 (-3.33%) ▼|UNH403.34+6.20 (+1.56%) ▲|UNP290.17+0.55 (+0.19%) ▲|UPS100.82-1.48 (-1.44%) ▼|USB62.83-0.55 (-0.86%) ▼|V368.69-6.38 (-1.70%) ▼|VZ50.13-0.02 (-0.03%) ▼|WFC88.83-1.14 (-1.27%) ▼|WMT106.07-1.08 (-1.00%) ▼|XOM159.49+0.02 (+0.01%) ▲|AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM185.54+3.01 (+1.65%) ▲|QCOM174.78+6.04 (+3.58%) ▲|RTX199.49-1.30 (-0.65%) ▼|SBUX102.27-2.20 (-2.11%) ▼|SCHW108.52-0.78 (-0.71%) ▼|SO88.89+0.78 (+0.89%) ▲|SPG211.61+2.17 (+1.04%) ▲|T25.50-0.18 (-0.70%) ▼|TMO605.92-7.86 (-1.28%) ▼|TMUS179.68-1.84 (-1.01%) ▼|TSLA367.79+13.71 (+3.87%) ▲|TXN257.14-1.30 (-0.50%) ▼|UBER73.24-2.52 (-3.33%) ▼|UNH403.34+6.20 (+1.56%) ▲|UNP290.17+0.55 (+0.19%) ▲|UPS100.82-1.48 (-1.44%) ▼|USB62.83-0.55 (-0.86%) ▼|V368.69-6.38 (-1.70%) ▼|VZ50.13-0.02 (-0.03%) ▼|WFC88.83-1.14 (-1.27%) ▼|WMT106.07-1.08 (-1.00%) ▼|XOM159.49+0.02 (+0.01%) ▲|

27.4 C

New York

Tuesday, September 8, 2026

Laramide Resources Files NI 43-101 Technical Report for the Westmoreland Uranium Project

Pool Safe Announces Appointment of Deacon as Chief Executive Officer and Adoption of Semi-Annual Financial Reporting

/C O R R E C T I O N — PG&E Corporation/

Tag: sessions

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsSessions